European Patent Office Revokes Myriad's BRCA1 Patent


Munich - After a public hearing in mid-May the European Patent Office (EPO) revoked one of three patents covering the predictive cancer DNA tests of the US company Myriad Genetics Inc. (EP 699. 754). Myriad's BRCA1 and BRCA2 tests identify genetic alterations that correlate with a higher risk to get breast cancer or ovarian tumors.
With the decision the EPO panel agreed with the arguments of a research consortium led by French Institute Curie. The researchers criticized that the protected DNA sequence for the BRCA1 test already had been published before Myriad's patent application and that the wide claims of the patent are hindering research. But in contrast to fundamental opponents to DNA patents like Greenpeace the researchers do not reject DNA patenting as such.
The decision will not affect Myriad's business, because the company did not sell the breast cancer test to any of the 28 European countries that follow the EPO's policies. However a spokesman announced that Myriad is to appeal against the decision.The company markets the test in the US, where it sells for around $2,500 as part of a BRCA1 and BRCA2 panel.
However the patent “has been the subject of public discussion ever since,” an EPO spokesman said. “Oppositions to the patent were filed in October 2001 by a number of parties including the Institut Curie.” A written statement of reasons for the opposition will be published in the next few months, a EPO spokesman said. The other two Myriad patents will be reviewed by the EPO in 2005.

Politics / Law


The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review


The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review


Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review


Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review


The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial


Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial


Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM


Image Gallery

Stock list

All quotes


  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%


  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%


  • WILEX (D)0.92 EUR53.3%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%


  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-44.9%
  • PROTHENA PLC (IE)28.07 USD-40.8%


  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%


  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 19.04.2014

Current issue

All issues

Product of the week



All Events



BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper